Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06481306
NCT06481306RecruitingPhase 1

A Phase 1/2a, First-in-human, Randomized, Double-blinded, Placebo-controlled, Dose-finding Study in Healthy Volunteers and Participants With Sickle Cell Disease to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, pH and Food Effect, and Preliminary Efficacy of BMS-986470

Bristol-Myers Squibb42 sites in 5 countries224 target enrollmentStarted: July 17, 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Recruiting
Enrollment
224
Locations
42
Primary Endpoint
Proportion of participants achieving HbF ≥ 10%
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics, pH and food effect, and preliminary efficacy of BMS-986470 in healthy volunteers and participants with sickle cell disease.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •Healthy male and female (who are not of childbearing potential) participants, as determined by the investigator based on medical history and other determinations. Females not of childbearing potential must have been amenorrhoeic for at least 12 months without an alternative medical cause and have follicle-stimulating hormone (FSH) levels of at least 40 IU/L or have undergone a hysterectomy, bilateral oophorectomy, or bilateral salpingectomy.
  • •Body mass index (BMI) of 18.0 to 32.0 kg/m2, inclusive. BMI = weight (kg)/[height (m)]2 as measured at screening.
  • •No evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG, or clinical laboratory assessments beyond what is consistent with the target population.
  • •Participants with a documented diagnosis of sickle cell disease (SCD) with genotype HbSS, HbSβ0-thal, or HbSβ+-thal.
  • •For Cohort B Part 1 only: Participants with ≥ 4 vaso-occlusive crises (VOCs) within the previous 12 months or ≥ 2 VOCs within the previous 6 months. For Cohort B Part 2 only: Participants with ≥ 2 VOCs and ≤ 15 VOCs within the previous 12 months.
  • •Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
  • •Participants must have the following laboratory values:
  • •i) Hemoglobin ≥ 5.5 and ≤ 12 g/dL (males) or ≥ 5.5 and ≤ 10.6 g/dL (females). ii) Absolute neutrophil count ≥ 1500/μL. iii) Platelet count ≥ 100 × 10^3/μL. iv) Absolute reticulocyte count > 100 × 10^3/μL or > 50 × 10^3/μL if taking hydroxyurea.

Exclusion Criteria

  • •Any significant medical condition or any condition that confounds the ability to interpret data from the study.
  • •Participant has any condition, including the presence of laboratory abnormalities, that places the participant at unacceptable risk if the participant was to participate in the study.
  • •Any major surgery or planned surgery (except GI surgery) within 12 weeks of the first study intervention administration.
  • •Participants with any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.
  • •For Cohort B Part 1 only: participants with more than 6 severe VOCs defined as VOCs requiring ≥ 24 hours of hospital admission within 12 months prior to the first dose of study intervention.
  • •For Cohort B Part 1 only: participants with any episode of acute chest syndrome within the last 6 months prior to the first dose of study intervention.
  • •Creatinine clearance (CrCl) < 60 mL/min/1.72m2 using Chronic Kidney Disease Epidemiology (CKD-EPI) equation.
  • •Cohort A and B:
  • •Participant is receiving regularly scheduled RBC or platelet transfusions or has received a RBC transfusion within 28 days and a platelet transfusion within 14 days prior to starting treatment with BMS-
  • •Other protocol-defined Inclusion/Exclusion criteria apply.

Arms & Interventions

Cohort A Part 3

Experimental

Intervention: Pantoprazole (Drug)

Cohort A Part 3

Experimental

Intervention: Famotidine (Drug)

Cohort B Part 1

Experimental

Intervention: Placebo (Drug)

Cohort A Part 1

Experimental

Intervention: BMS-986470 (Drug)

Cohort A Part 2

Experimental

Intervention: BMS-986470 (Drug)

Cohort A Part 1

Experimental

Intervention: Placebo (Drug)

Cohort A Part 2

Experimental

Intervention: Placebo (Drug)

Cohort A Part 3

Experimental

Intervention: BMS-986470 (Drug)

Cohort B Part 2

Experimental

Intervention: BMS-986470 (Drug)

Cohort B Part 1

Experimental

Intervention: BMS-986470 (Drug)

Outcomes

Primary Outcomes

Proportion of participants achieving HbF ≥ 10%

Time Frame: Up to 28 days after last dose

Proportion of participants achieving HbF ≥ 20%

Time Frame: Up to 28 days after last dose

Proportion of participants achieving HbF ≥ 30%

Time Frame: Up to 28 days after last dose

Number of participants with adverse events (AEs)

Time Frame: Up to 26 months

Number of participants with serious adverse events (SAEs)

Time Frame: Up to 26 months

Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria

Time Frame: Up to 26 months

Number of participants with AEs leading to discontinuation

Time Frame: Up to 26 months

Number of deaths

Time Frame: Up to 26 months

Secondary Outcomes

  • Maximum observed plasma concentration (Cmax)(Up to Day 28)
  • Area under the concentration-time curve (AUC)(Up to Day 28)
  • Time of maximum observed plasma concentration (Tmax)(Up to Day 28)
  • Dose proportionality of BMS-986470 for Cmax and AUC(Up to Day 28)
  • Change from baseline in total Hb fractions: adult Hb (HbA)(Up to Day 28)
  • Median time to achieve HbF ≥ 10%(Up to 26 months)
  • Median duration of HbF at or above 10%(Up to 26 months)
  • Median time to achieve HbF ≥ 20%(Up to 26 months)
  • Median duration of HbF at or above 20%(Up to 26 months)
  • Median time to achieve HbF ≥ 30%(Up to 26 months)
  • Median duration of HbF at or above 30%(Up to 26 months)
  • Number of participants achieving HbF ≥ 30%(Up to 26 months)
  • Number of participants achieving HbF ≥ 20%(Up to 26 months)
  • Maximum observed plasma concentration (Cmax)(Up to Day 28)
  • Area under the concentration-time curve (AUC)(Up to Day 28)
  • Time of maximum observed plasma concentration (Tmax)(Up to Day 28)
  • Dose proportionality of BMS-986470 for Cmax and AUC(Up to Day 28)
  • Change from baseline in total hemoglobin (Hb)(Up to 26 months)
  • Change from baseline in total Hb fractions: adult Hb (HbA)(Up to Day 28)
  • Change from baseline in total Hb fractions: fetal Hb (HbF)(Up to 26 months)
  • Change from baseline in total Hb fractions: sickle Hb (HbS)(Up to 26 months)
  • Change from baseline in markers of red blood cell (RBC) lysis: total Hb(Up to 26 months)
  • Change from baseline in markers of RBC lysis: aspartate aminotransferase (AST)(Up to 26 months)
  • Change from baseline in markers of RBC lysis: lactate dehydrogenase (LDH)(Up to 26 months)
  • Change from baseline in markers of RBC lysis: total bilirubin(Up to 26 months)
  • Change from baseline in markers of RBC lysis: indirect bilirubin(Up to 26 months)
  • Change from baseline in markers of RBC lysis: haptoglobin(Up to 26 months)
  • Change from baseline in markers of RBC lysis: absolute reticulocyte count(Up to 26 months)
  • Change from baseline in markers of RBC lysis: reticulocyte percentage of RBCs(Up to 26 months)
  • Number of participants achieving HbF ≥ 10%(Up to 26 months)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (42)

Loading locations...

Similar Trials

Completed
Phase 1
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)Ulcerative Colitis
NCT04924114Merck Sharp & Dohme LLC57
Completed
Phase 1
PK Profile and Preliminary Efficacy of TNP-2092 Capsules in Liver Cirrhosis Patients With HyperammonemiaHyperammonemia
NCT06135675TenNor Therapeutics (Suzhou) Limited36
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 or CT-G11 and Food Effect of CT-G20 in Human ParticipantsHealthy
NCT03918967Celltrion72
Completed
Phase 1
Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Study Of PF-04447943, Co-Administered With And Without Hydroxyurea, In Subjects With Stable Sickle Cell DiseasePhase 1 Sickle Cell
NCT02114203Pfizer30
Recruiting
Phase 1
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple MyelomaPlasma Cell DisorderMultiple Myeloma
NCT04879043Heidelberg Pharma AG78